RYLAZE FDA approval date

The FDA approved RYLAZE on 30 Jun 2021.

FDA approval date
30 Jun 2021

Drug identity has not yet been verified against registry records

Also recorded as ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2021-06-30DayRYLAZEFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761179", "applicant_as_listed_by_fda": "JAZZ PHARMS", "brand_names": ["RYLAZE"], "active_ingredients": ["ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20210630", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026